Department of Oncology, Hadassah-University Hospital, Jerusalem, Israel.
PLoS One. 2010 Jun 15;5(6):e11135. doi: 10.1371/journal.pone.0011135.
While protease-activated-receptor 1 (PAR(1)) plays a central role in tumor progression, little is known about the cell signaling involved.
METHODOLOGY/PRINCIPAL FINDINGS: We show here the impact of PAR(1) cellular activities using both an orthotopic mouse mammary xenograft and a colorectal-liver metastasis model in vivo, with biochemical analyses in vitro. Large and highly vascularized tumors were generated by cells over-expressing wt hPar1, Y397Z hPar1, with persistent signaling, or Y381A hPar1 mutant constructs. In contrast, cells over-expressing the truncated form of hPar1, which lacks the cytoplasmic tail, developed small or no tumors, similar to cells expressing empty vector or control untreated cells. Antibody array membranes revealed essential hPar1 partners including Etk/Bmx and Shc. PAR(1) activation induces Etk/Bmx and Shc binding to the receptor C-tail to form a complex. Y/A mutations in the PAR(1) C-tail did not prevent Shc-PAR(1) association, but enhanced the number of liver metastases compared with the already increased metastases obtained with wt hPar1. We found that Etk/Bmx first binds via the PH domain to a region of seven residues, located between C378-S384 in PAR(1) C-tail, enabling subsequent Shc association. Importantly, expression of the hPar1-7A mutant form (substituted A, residues 378-384), which is incapable of binding Etk/Bmx, resulted in inhibition of invasion through Matrigel-coated membranes. Similarly, knocking down Etk/Bmx inhibited PAR(1)-induced MDA-MB-435 cell migration. In addition, intact spheroid morphogenesis of MCF10A cells is markedly disrupted by the ectopic expression of wt hPar1. In contrast, the forced expression of the hPar1-7A mutant results in normal ball-shaped spheroids. Thus, by preventing binding of Etk/Bmx to PAR(1) -C-tail, hPar1 oncogenic properties are abrogated.
CONCLUSIONS/SIGNIFICANCE: This is the first demonstration that a cytoplasmic portion of the PAR(1) C-tail functions as a scaffold site. We identify here essential signaling partners, determine the hierarchy of binding and provide a platform for therapeutic vehicles via definition of the critical PAR(1)-associating region in the breast cancer signaling niche.
尽管蛋白酶激活受体 1(PAR1)在肿瘤进展中起着核心作用,但涉及的细胞信号传导却知之甚少。
方法/主要发现:我们在此展示了使用体内的同源小鼠乳腺异种移植和结直肠-肝转移模型以及体外的生化分析,对 PAR1 细胞活性的影响。通过过度表达 wt hPar1、具有持续信号的 Y397Z hPar1 或 Y381A hPar1 突变构建体的细胞生成了大而血管丰富的肿瘤。相比之下,过度表达缺乏细胞质尾巴的 hPar1 截断形式的细胞仅产生小肿瘤或不产生肿瘤,类似于表达空载体或未经处理的对照细胞的细胞。抗体阵列膜揭示了包括 Etk/Bmx 和 Shc 在内的基本 hPar1 伴侣。PAR1 激活诱导 Etk/Bmx 和 Shc 与受体 C 尾结合形成复合物。PAR1 C 尾中的 Y/A 突变不仅阻止了 Shc-PAR1 结合,但与已经用 wt hPar1 获得的增加的肝转移相比,增加了肝转移的数量。我们发现,Etk/Bmx 首先通过 PH 结构域与位于 PAR1 C 尾中的七个残基的区域结合,该区域位于 C378-S384 之间,从而允许随后的 Shc 结合。重要的是,表达不能与 Etk/Bmx 结合的 hPar1-7A 突变形式(取代 A,残基 378-384)会抑制穿过 Matrigel 涂层膜的侵袭。同样,敲低 Etk/Bmx 抑制了 PAR1 诱导的 MDA-MB-435 细胞迁移。此外,MCF10A 细胞完整球体形态发生的明显破坏是由 wt hPar1 的异位表达引起的。相比之下,hPar1-7A 突变体的强制表达导致正常的球形球体。因此,通过防止 Etk/Bmx 与 PAR1-C 尾结合,hPar1 的致癌特性被消除。
结论/意义:这是第一个证明 PAR1 C 尾的细胞质部分作为支架位点发挥作用的证明。我们在此确定了基本的信号传导伴侣,确定了结合的层次结构,并通过定义乳腺癌信号龛中的关键 PAR1 相关区域,为治疗载体提供了一个平台。